SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stemline Therapeutics, Inc. - STML

NEW YORK, Feb. 2, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stemline Therapeutics, Inc. ("Stemline" or the "Company") (NASDAQ: STML). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Stemline and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On February 2, 2017, Bloomberg reported that a patient in a clinical trial of the Company's cancer drug SL-401 died from a severe side effect, the third death linked to the same SL-401 toxicity. 

On this news, the Company's stock has fallen as much as $3.50, or over 35.90% to a low of $6.20 during intra-day trading on February 2, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-stemline-therapeutics-inc---stml-300401416.html

SOURCE Pomerantz LLP